Studies of small molecule metabolites in human found that, changes in metabolic levels have occurred in the early stage of pathophysiological alterations caused by diseases. Therefore, metabolomics can describe a metabolic changes in body before the clinical symptoms appear. Compare with the normal people, find the disease risk factors, diagnostic factors of disease classification and development, providing new indicators for disease prevention and clinical diagnosis.

Metabolomics has shown unique advantages and necessity in gaining insight into disease progression and molecular mechanisms. When differential metabolites are identified, the integration of human metabolomic data with relevant gene expression, genetic information and known complex disease loci can help describe the precise metabolic pathway alterations associated with metabolic phenotypes under specific genetic regulation, providing new ideas for new drug development and disease mechanism research.

With the continuous deepening research in diseases, it has been found that there are large individual differences in response to drugs. These differences cause certain difficulties for doctors by treating diseases. Therefore, medicine instruction and reduction of toxic side effects are of great significance. Metabolomics is used to understand the disease disruption networks, find evaluation indicators after disease treatment, and provide evaluation basis for disease treatment plans, therapeutic efficacy and adverse reaction interventions.

Prognostic analysis is a prediction of various disease outcomes, which is useful for clinical decision. Metabolomics technology is used to find factors that affect disease severity or progression, and in combination with traditional prognostic factors, construct models for predicting disease recurrence ,to provide doctors with treatment decisions and improve disease prognosis.